WO2009061431A3 - Compositions for the treatment and prevention of eyelid swelling comprising an osmotically active ingredient and a vasoconstrictor - Google Patents

Compositions for the treatment and prevention of eyelid swelling comprising an osmotically active ingredient and a vasoconstrictor Download PDF

Info

Publication number
WO2009061431A3
WO2009061431A3 PCT/US2008/012513 US2008012513W WO2009061431A3 WO 2009061431 A3 WO2009061431 A3 WO 2009061431A3 US 2008012513 W US2008012513 W US 2008012513W WO 2009061431 A3 WO2009061431 A3 WO 2009061431A3
Authority
WO
WIPO (PCT)
Prior art keywords
vasoconstrictor
prevention
treatment
compositions
active ingredient
Prior art date
Application number
PCT/US2008/012513
Other languages
French (fr)
Other versions
WO2009061431A2 (en
Inventor
Matthew Jonathan Chapin
Mark Barry Abelson
Keith Jeffrey Lane
George Minno
Original Assignee
Aciex Inc
Matthew Jonathan Chapin
Mark Barry Abelson
Keith Jeffrey Lane
George Minno
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aciex Inc, Matthew Jonathan Chapin, Mark Barry Abelson, Keith Jeffrey Lane, George Minno filed Critical Aciex Inc
Priority to AU2008325214A priority Critical patent/AU2008325214A1/en
Priority to BRPI0819105A priority patent/BRPI0819105A2/en
Priority to JP2010533093A priority patent/JP2011503061A/en
Priority to CA2705050A priority patent/CA2705050A1/en
Priority to EP08847794A priority patent/EP2219630A2/en
Priority to MX2010005012A priority patent/MX2010005012A/en
Priority to CN2008801191850A priority patent/CN101977595A/en
Publication of WO2009061431A2 publication Critical patent/WO2009061431A2/en
Publication of WO2009061431A3 publication Critical patent/WO2009061431A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

The invention features topical formulations comprising an osmotically active agent and/or a vasoconstrictor and/or an astringent agent for the treatment and prevention of eyelid swelling, and methods of use thereof.
PCT/US2008/012513 2007-11-08 2008-11-06 Compositions for the treatment and prevention of eyelid swelling comprising an osmotically active ingredient and a vasoconstrictor WO2009061431A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
AU2008325214A AU2008325214A1 (en) 2007-11-08 2008-11-06 Compositions for the treatment and prevention of eyelid swelling comprising an osmotically active ingredient and a vasoconstrictor
BRPI0819105A BRPI0819105A2 (en) 2007-11-08 2008-11-06 composition for the treatment and prevention of eyelid edema
JP2010533093A JP2011503061A (en) 2007-11-08 2008-11-06 Composition for the treatment and prevention of eyelid swelling comprising an osmotically active agent and a vasoconstrictor
CA2705050A CA2705050A1 (en) 2007-11-08 2008-11-06 Compositions for the treatment and prevention of eyelid swelling
EP08847794A EP2219630A2 (en) 2007-11-08 2008-11-06 Compositions for the treatment and prevention of eyelid swelling comprising an osmotically active ingredient and a vasoconstrictor
MX2010005012A MX2010005012A (en) 2007-11-08 2008-11-06 Compositions for the treatment and prevention of eyelid swelling.
CN2008801191850A CN101977595A (en) 2007-11-08 2008-11-06 Compositions for the treatment and prevention of eyelid swelling

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US751107P 2007-11-08 2007-11-08
US61/007,511 2007-11-08

Publications (2)

Publication Number Publication Date
WO2009061431A2 WO2009061431A2 (en) 2009-05-14
WO2009061431A3 true WO2009061431A3 (en) 2009-07-23

Family

ID=40329067

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/012513 WO2009061431A2 (en) 2007-11-08 2008-11-06 Compositions for the treatment and prevention of eyelid swelling comprising an osmotically active ingredient and a vasoconstrictor

Country Status (8)

Country Link
EP (1) EP2219630A2 (en)
JP (1) JP2011503061A (en)
CN (1) CN101977595A (en)
AU (1) AU2008325214A1 (en)
BR (1) BRPI0819105A2 (en)
CA (1) CA2705050A1 (en)
MX (1) MX2010005012A (en)
WO (1) WO2009061431A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120225918A1 (en) * 2011-03-03 2012-09-06 Voom, Llc Compositions and Methods for Non-Surgical Treatment of Ptosis
IN2014CN03950A (en) * 2011-11-01 2015-10-16 Rohto Pharma
EA021247B1 (en) * 2012-03-26 2015-05-29 Ооо "Фармацевтическая Компания "Славянская Аптека" Pharmaceutical composition having vasoconstricting, anticongestant, anti-inflammatory activity (embodiments)
EA021234B1 (en) * 2012-03-27 2015-05-29 Ооо "Фармацевтическая Компания "Славянская Аптека" Pharmaceutical composition having vasoconstricting, anticongestant, anti-inflammatory activity (embodiments)
JP6373551B2 (en) * 2012-05-30 2018-08-15 味の素株式会社 Gallotannin-containing composition
AU2013201465B2 (en) 2012-10-24 2016-03-03 Rayner Surgical (Ireland) Limited Stable preservative-free mydriatic and anti-inflammatory solutions for injection
US20140329874A1 (en) * 2013-05-06 2014-11-06 Allergan, Inc. Alpha adrenergic agonists for the treatment of tissue trauma
TWI809304B (en) 2014-12-01 2023-07-21 奥默羅斯公司 Anti-inflammatory and mydriatic intracameral solutions for inhibition of postoperative ocular inflammatory conditions
US9820954B2 (en) 2015-08-19 2017-11-21 Jenivision Inc. Quantitative peri-orbital application of ophthalmology drugs
CN108883308A (en) * 2016-01-26 2018-11-23 利维申制药有限公司 The composition and purposes of alpha-adrenergic medicament
EP3970803A1 (en) * 2020-09-22 2022-03-23 Beiersdorf AG Cosmetic composition of low osmolality
WO2022187306A1 (en) * 2021-03-03 2022-09-09 Voom, Llc Compositions and methods for treatment of blepharitis

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2618428A (en) * 1947-01-27 1952-11-18 John K M Harrison Shock resistant container
WO1992000707A1 (en) * 1990-07-06 1992-01-23 Insite Vision Incorporated Topical ophthalmic suspensions
EP0517160A1 (en) * 1991-06-07 1992-12-09 Inverni Della Beffa S.P.A. Extended-release ophthalmic preparations
US5811446A (en) * 1997-04-18 1998-09-22 Cytos Pharmaceuticals Llc Prophylactic and therapeutic methods for ocular degenerative diseases and inflammations and histidine compositions therefor
WO2000037080A1 (en) * 1998-12-22 2000-06-29 Bausch & Lomb Incorporated Ophthalmic compositions comprising pheniramine and povidone
JP2001187728A (en) * 1999-12-28 2001-07-10 Lion Corp Ophthalmic composition
DE10000612A1 (en) * 2000-01-10 2001-07-19 Min Becker Aqueous active substance preparations, especially eye drops, nasal drops and nasal sprays, contain sodium chloride in place of preservatives
JP2002308775A (en) * 2001-04-06 2002-10-23 Rohto Pharmaceut Co Ltd External composition
US20050147679A1 (en) * 1998-03-24 2005-07-07 Petito George D. Composition and method for healing tissues
US20060057081A1 (en) * 2004-09-13 2006-03-16 Boxrud Cynthia A Compositions and methods for treatment of skin discoloration
US20060110331A1 (en) * 2004-11-24 2006-05-25 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
JP2006232792A (en) * 2005-02-21 2006-09-07 Aile De Beaute:Kk Skin ageing-improving cosmetic
WO2007127333A2 (en) * 2006-04-26 2007-11-08 Aciex, Inc. Compositions for the treatment and prevention of eyelid swelling
US20080051385A1 (en) * 2006-03-31 2008-02-28 Jagdish Parasrampuria Ocular allergy treatments

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2618428A (en) * 1947-01-27 1952-11-18 John K M Harrison Shock resistant container
WO1992000707A1 (en) * 1990-07-06 1992-01-23 Insite Vision Incorporated Topical ophthalmic suspensions
EP0517160A1 (en) * 1991-06-07 1992-12-09 Inverni Della Beffa S.P.A. Extended-release ophthalmic preparations
US5811446A (en) * 1997-04-18 1998-09-22 Cytos Pharmaceuticals Llc Prophylactic and therapeutic methods for ocular degenerative diseases and inflammations and histidine compositions therefor
US20050147679A1 (en) * 1998-03-24 2005-07-07 Petito George D. Composition and method for healing tissues
WO2000037080A1 (en) * 1998-12-22 2000-06-29 Bausch & Lomb Incorporated Ophthalmic compositions comprising pheniramine and povidone
JP2001187728A (en) * 1999-12-28 2001-07-10 Lion Corp Ophthalmic composition
DE10000612A1 (en) * 2000-01-10 2001-07-19 Min Becker Aqueous active substance preparations, especially eye drops, nasal drops and nasal sprays, contain sodium chloride in place of preservatives
JP2002308775A (en) * 2001-04-06 2002-10-23 Rohto Pharmaceut Co Ltd External composition
US20060057081A1 (en) * 2004-09-13 2006-03-16 Boxrud Cynthia A Compositions and methods for treatment of skin discoloration
US20060110331A1 (en) * 2004-11-24 2006-05-25 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
JP2006232792A (en) * 2005-02-21 2006-09-07 Aile De Beaute:Kk Skin ageing-improving cosmetic
US20080051385A1 (en) * 2006-03-31 2008-02-28 Jagdish Parasrampuria Ocular allergy treatments
WO2007127333A2 (en) * 2006-04-26 2007-11-08 Aciex, Inc. Compositions for the treatment and prevention of eyelid swelling

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 200169, Derwent World Patents Index; AN 2001-605287, XP002527206 *
DATABASE WPI Week 200335, Derwent World Patents Index; AN 2003-367023, XP002527205 *
DATABASE WPI Week 200663, Derwent World Patents Index; AN 2006-607199, XP002527207 *
GREINER J V ET AL: "A comparison of the clinical efficacy of pheniramine maleate/naphazoline hydrochloride ophthalmic solution and olopatadine hydrochloride ophthalmic solution in the conjunctival allergen challenge model", CLINICAL THERAPEUTICS, EXCERPTA MEDICA, PRINCETON, NJ, US, vol. 27, no. 5, 1 May 2005 (2005-05-01), pages 568 - 577, XP004949048, ISSN: 0149-2918 *
ONO S J ET AL: "Allergic conjunctivitis: Update on pathophysiology and prospects for future treatment", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, MOSBY - YEARLY BOOK, INC, US, vol. 115, no. 1, 1 January 2005 (2005-01-01), pages 118 - 122, XP004757383, ISSN: 0091-6749 *

Also Published As

Publication number Publication date
BRPI0819105A2 (en) 2019-09-24
CN101977595A (en) 2011-02-16
EP2219630A2 (en) 2010-08-25
JP2011503061A (en) 2011-01-27
CA2705050A1 (en) 2009-05-14
AU2008325214A1 (en) 2009-05-14
MX2010005012A (en) 2010-06-23
WO2009061431A2 (en) 2009-05-14

Similar Documents

Publication Publication Date Title
WO2009061431A3 (en) Compositions for the treatment and prevention of eyelid swelling comprising an osmotically active ingredient and a vasoconstrictor
WO2007127333A3 (en) Compositions for the treatment and prevention of eyelid swelling
WO2009074735A3 (en) Use of a novel natural agent in cosmetic compositions
WO2005079143A3 (en) Topical formulations for the treatment of skin conditions
WO2006096439A3 (en) Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
WO2007002597A3 (en) Modified-release formulations of a bupropion salt
WO2006096434A3 (en) Pharmaceutical compositions for the treatment and/or prevention of anxiety disorders
ZA200709251B (en) Suspension formulations comprising an active principle, a poloxamer or meroxapol surfactant and a glycol, its use for the manufacture of a medicament for treating ophthalmic disorders
WO2012027065A3 (en) Combination therapy for treatment of disease
WO2007027527A3 (en) Isoindole-imide compounds and compositions comprising and methods of using the same
WO2006042146A3 (en) Multifunctional nanoparticles conjugates and their use
WO2007011962A3 (en) Treatment of cancer
WO2009056550A3 (en) Bupropion hydrobromide and therapeutic applications
WO2005091853A3 (en) Methods and compositions for treating il-13 related pathologies
WO2008070670A3 (en) Enhanced immediate release formulations of topiramate
WO2009141541A3 (en) Use of kif13a and ap-1 inhibitors for inhibiting melanogenesis
WO2006121964A3 (en) Ophthalmic suspension comprising an ophthalmic drug, a poloxamine and a glycol tonicity-adjusting agent, use of said composition for the manufacture of a medicament for treating ophthalmic disorders
WO2010021607A3 (en) Pharmaceutical formulation
WO2009019294A3 (en) Bupropion hydrobromide and therapeutic applications
WO2006076097A3 (en) Stable non-crystalline formulation comprising losartan
WO2009032843A3 (en) Deuterated ethambutols and their use
WO2007133944A3 (en) Topical administration of acyclovir
WO2006131401A3 (en) Controlled release of a drug through skin on the basis of a topical composition comprising a drug, a film-forming silicone and at least one volatile solvent
WO2008136034A3 (en) Ophthalmic compositions for the treatment of ocular hypertension and glaucoma
WO2007009691A3 (en) Combination of substituted pyrazolines and anti -addictive agent

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880119185.0

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08847794

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2008325214

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2705050

Country of ref document: CA

Ref document number: MX/A/2010/005012

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2010533093

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 1731/KOLNP/2010

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2008325214

Country of ref document: AU

Date of ref document: 20081106

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2008847794

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0819105

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20100507